Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Mixed Price Action

Open Interest and Volume Dynamics

On 25 June 2026, Glenmark’s open interest (OI) in derivatives rose sharply to 58,146 contracts from 52,055 the previous day, marking an increase of 6,091 contracts or 11.7%. This expansion in OI suggests that fresh positions are being established rather than existing ones being squared off, indicating increased trader interest and potential directional conviction.

Simultaneously, the volume traded stood at 20,501 contracts, reflecting robust participation in the derivatives market. The futures segment alone accounted for a notional value of approximately ₹1,07,693 lakhs, while options contributed a staggering ₹6,165 crores in notional value, underscoring the significant liquidity and interest in Glenmark’s options chain.

The combined notional value of futures and options contracts reached ₹1,08,126 lakhs, highlighting the stock’s active derivatives market presence. This liquidity supports sizeable trade sizes, with the stock’s liquidity comfortably accommodating trades worth ₹2.36 crores based on 2% of the five-day average traded value.

Price Performance and Moving Averages

Despite the surge in derivatives activity, Glenmark’s stock price underperformed its sector by 0.57% on the day, registering a decline of 0.64%. The one-day return was -0.53%, lagging behind the Pharmaceuticals & Biotechnology sector’s marginal dip of 0.02% and the broader Sensex’s gain of 0.74%.

Technically, the stock is trading above its 200-day moving average, a long-term bullish indicator, but remains below its 5-day, 20-day, 50-day, and 100-day moving averages. This mixed technical picture suggests short- to medium-term pressure despite a solid long-term base, possibly reflecting profit-booking or cautious positioning by investors.

Investor participation appears to be waning, with delivery volumes on 24 June falling sharply by 59.9% to 1.11 lakh shares compared to the five-day average. This decline in delivery volume indicates reduced conviction among long-term holders, even as derivatives activity intensifies.

Market Positioning and Potential Directional Bets

The sharp rise in open interest alongside a slight price decline suggests that market participants may be positioning for increased volatility or a directional move in the near term. The increase in OI typically reflects new money entering the market, which can be either bullish or bearish depending on the nature of the contracts.

Given Glenmark’s current trading below short- and medium-term moving averages but above the 200-day average, traders might be hedging against a potential pullback or preparing for a rebound. The elevated options notional value indicates active call and put writing, which could imply a range-bound outlook or anticipation of a significant event impacting the stock.

Furthermore, the mid-cap pharmaceutical company’s Mojo Score of 71.0 and a current Mojo Grade of Buy (downgraded from Strong Buy on 1 June 2026) reflect a cautiously optimistic stance from MarketsMOJO’s quantitative model. This downgrade signals a slight moderation in confidence, possibly due to recent price underperformance and reduced investor participation.

Investors should note that Glenmark’s market capitalisation stands at ₹61,212.18 crores, placing it firmly in the mid-cap category, which often entails higher volatility compared to large-cap peers. The pharmaceutical sector remains sensitive to regulatory developments, patent outcomes, and global health trends, all of which could influence directional bets.

Sector and Benchmark Comparison

In comparison to the Pharmaceuticals & Biotechnology sector, which showed a near-flat performance on the day, Glenmark’s underperformance and increased derivatives activity may indicate stock-specific factors at play. The Sensex’s positive return of 0.74% further accentuates Glenmark’s relative weakness, suggesting that the stock is currently out of favour among broader market participants.

However, the stock’s position above the 200-day moving average provides a technical floor, which could attract value-oriented investors if the price stabilises. The divergence between derivatives market enthusiasm and spot price weakness often precedes significant price movements, warranting close monitoring of open interest trends and volume patterns in the coming sessions.

Implications for Investors and Traders

For investors, the current scenario suggests a need for caution. The decline in delivery volumes indicates reduced long-term conviction, while the derivatives market’s heightened activity points to speculative positioning. Those with a bullish outlook may consider the stock’s strong long-term technical support and favourable Mojo Score as reasons to accumulate selectively.

Conversely, traders might exploit the increased volatility and open interest build-up by employing strategies such as straddles or spreads in the options market to capitalise on potential price swings. Monitoring the evolution of open interest in calls versus puts will be crucial to discerning whether the market consensus is leaning bullish or bearish.

Given the pharmaceutical sector’s inherent sensitivity to external factors, including regulatory approvals and global health developments, Glenmark’s derivatives activity could also be reflecting anticipation of upcoming news or earnings announcements.

In summary, Glenmark Pharmaceuticals Ltd. is currently at a crossroads, with a significant surge in open interest signalling active market positioning amid mixed price and volume signals. Investors and traders alike should remain vigilant, analysing both technical indicators and fundamental developments to navigate the stock’s near-term trajectory effectively.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today